Answers are grounded in this paper and cite their sources.
A trio of former executives at Johnson & Johnson has banded together to launch a start-up focused on next-generation biologics. Former J&J oncology R&D head Peter F. Lebowitz, former head of Janssen Biotherapeutics Sanjaya Singh, and former J&J vice president and head of oncology discovery and external innovation Joe Erhardt are behind Third Arc Bio. The company aims to develop antibodies that engage T cells such that they can be used to treat solid-tumor cancers and inflammatory and immunological diseases. The company has $165 million in venture backing from Goldman Sachs and AbbVie, among others.
No takes yet. Share an insight, caveat, or question.
Rowan Walrath (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: